Tetracosactide (Synacthen Depot 1 mg/1 mL)
Tetracosactide risk profile, scheduling, and guidance for claims professionals and care workers . Also known as Synacthen Depot 1 mg/1 mL.
Tetracosactide (brand names: Synacthen Depot 1 mg/1 mL) is classified as Low risk (2 risk points) by AllMeds. It is a S4 medication under the TGA in Australia. ACTH analog causing corticosteroid effects with potential mood and cognitive impacts.
Key Takeaways
- TGA Schedule: S4 in Australia
- Risk level: Low (2 points)
- Recommended maximum duration: 3 days
- PBS listed: Subsidised under the Australian Pharmaceutical Benefits Scheme
Scheduling and Classification
| Jurisdiction | Classification | Status |
|---|---|---|
| Australia (TGA) | S4 | PBS listed |
Risk Profile
ACTH analog causing corticosteroid effects with potential mood and cognitive impacts.
Regulatory and Compliance Guidance
When Tetracosactide appears on a claimant's medication list, claims professionals should assess whether the prescribing is appropriate for the compensable injury, whether the duration is within guidelines, and whether there are interactions with other medications on the claim.
Australia TGA / PBS / State Schemes
Classified as S4 under the Therapeutic Goods Administration (TGA).
Listed on the Pharmaceutical Benefits Scheme (PBS) for subsidised prescribing.
Need to assess this medication across your caseload?
Run a full risk assessment including Tetracosactide interactions and compliance checks.
AllMeds gives you instant risk assessments, compliance checks, and automated letters for every medication on a claim.
No credit card required. No signup for your first 2 questions.
Medical Disclaimer: This content is for informational purposes for claims professionals and care workers. It is not medical advice. Always consult a qualified healthcare professional for clinical decisions. Drug information is sourced from TGA, FDA, MHRA, PBS, NICE, and CDC databases and may not reflect the latest updates. AllMeds does not replace clinical judgement.